#USA #Acquisition #Alpharetta #Avanos Medical #AIP

Avanos Medical to Be Acquired by American Industrial Partners

In a significant development for the medical technology sector, Avanos Medical, Inc. (NYSE: AVNS) has reached a definitive agreement for its acquisition by American Industrial Partners (AIP) in an all-cash deal valued at approximately $1.272 billion. The acquisition is poised to bring about considerable changes, not only for Avanos but also for its stakeholders, including employees and shareholders.

Details of the Acquisition Agreement

As part of the agreement, shareholders of Avanos will receive $25.00 for each share they own. This purchase price marks an impressive surge of around 72.1% compared to the company's closing stock price on April 13, 2026, the last trading day before the announcement. Moreover, it amounts to an 82.8% premium based on the average share price over the preceding 30 days.

Gary Blackford, chair of the Board at Avanos, asserts that this agreement exemplifies a pivotal moment for the company, reflecting the robust momentum in its operations. He emphasizes that after thorough deliberations with independent advisors, the board is convinced that aligning with AIP represents the optimal pathway for Avanos and its stakeholders. The board's view is that this move could maximize shareholder value, create exciting prospects for employees, and strategically position Avanos for sustained growth and success in the long run.

David Pacitti, the Chief Executive Officer of Avanos, shared his insights about the transition. Over recent years, Avanos has intentionally directed its focus to becoming a more streamlined medical technology entity, emphasizing areas where it can deliver substantial clinical value. He stated that collaborating with AIP would enhance Avanos’s ability to continue innovating while fortifying its competitive stance with the added flexibility and resources that AIP brings. Moreover, he highlighted AIP’s recognition of Avanos's talented workforce and their critical role in addressing pressing healthcare challenges today.

AIP's Perspective on the Acquisition

Joel Rotroff, a Partner at AIP, has praised Avanos as a distinct player in the medical technology landscape, holding strong positions in lucrative segments and presenting a compelling platform for ongoing growth. He expressed eagerness to partner with Avanos to further build upon the company’s current momentum and support the next phase of its innovation and execution strategy.

Sunny Li, another partner at AIP, reiterated their admiration for the management's efforts in steering Avanos toward growth and mentioned the remarkable quality of Avanos’ people and products. He indicated a firm belief that the collaboration, alongside AIP's extensive operational expertise, will propel management's vision and position Avanos favorably for long-term sustainability.

Anticipated Timeline and Transaction Conditions

The acquisition has received unanimous approval from Avanos’ Board of Directors and is expected to finalize in the latter half of 2026. However, completion hinges on standard conditions which include approval from Avanos' shareholders, the expiration of the necessary waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and the acquisition of additional regulatory permissions. Notably, the deal does not involve any financing contingencies.

Once the transaction is completed, Avanos will shift from being publicly traded to a private entity, leading to the removal of its common stock from the New York Stock Exchange. Avanos will maintain its headquarters in Alpharetta, Georgia, reinforcing its long-term commitment to this location.

In light of the acquisition announcement, Avanos has postponed its 2026 Annual Meeting of Stockholders, which was initially scheduled for April 21, 2026.

Advisory Role in the Transaction

J.P. Morgan Securities LLC is leading the financial advisory for Avanos while Alston & Bird, LLP is providing legal counsel. UBS Investment Bank has also acted as a financial advisor. Meanwhile, AIP is advised by Sidley Austin LLP for legal matters and Baker Botts LLP for regulatory guidance.

For further insights into Avanos Medical's commitment and performances, stakeholders are encouraged to visit their official website, where they can access more information about their innovations and product offerings.